Charis1000 / Ensol Biosci - LARVOL DELTA

Discovery of a transforming growth factor-β1 inhibitory peptide, Charis 1000 to enhance the therapeutic efficacy of paclitaxel in triple-negative breast cancer. (PubMed, Int J Biol Macromol) - "In vivo studies further revealed synergistic effects of C1K and PTX, resulting in enhanced apoptosis in both sensitive and PTX-resistant TNBC cells. These findings suggest that C1K effectively targets TGF-β to inhibit autophagy and potentiate the apoptotic effects of PTX, as a promising combinatorial therapeutic agent for improving treatment outcomes in TNBC patients."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • TGFB1

To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects (clinicaltrials.gov) - P1 | N=35 | Completed | Sponsor: Seoul National University Hospital | Recruiting ➔ Completed

Trial completion

Ensol Bio secures ‘C1K combination solution’ to overcome toxicity limitations of immunotherapy drugs [Google translation] (Global Economy News) - "Ensol Bioscience...confirmed that in an animal test of triple therapy adding C1K to the existing treatment method for triple negative breast cancer (TNBC), immunotherapy-chemotherapy combination therapy, the tumor volume was reduced by 59.3% with the combination of C1K....The triple combination clinical trial 1b/2a of immunotherapy - chemotherapy - C1K is scheduled to be conducted in the second half of 2024....As a result of a 3-week drug administration experiment, the efficacy of the triple combination treatment group was confirmed to reduce tumor volume growth by 77% compared to the negative control group, and a statistically significant 59.3% (p<0.001) reduction compared to the immunotherapy-chemo anticancer drug combination treatment group."

New P1/2 trial • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Ensol Bioscience | Recruiting ➔ Completed

Trial completion

To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: Seoul National University Hospital

New P1 trial

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: Ensol Bioscience

New P1 trial